Related Experiment Video

Updated: Jun 15, 2026

Ameliorating Osteoarthritis in Mice Using Silver Nanoparticles
05:50

Ameliorating Osteoarthritis in Mice Using Silver Nanoparticles

Published on: June 2, 2023

Novel therapies in OA

Carl R Flannery1

  • 1Pfizer, 200 CambridgePark Drive, Cambridge, MA 02140, USA. cflannery@wyeth.com

Current Drug Targets
|March 5, 2010
PubMed

Insights

Osteoarthritis (OA) treatment faces challenges, but research identifies targets like aggrecanases and collagenases for new therapies. Advances include targeting cytokines and using lubricin for cartilage health.

Area of Science:

  • Biomedical Science
  • Orthopedics
  • Pharmacology

Background:

  • Osteoarthritis (OA) pathophysiology presents a significant unmet medical challenge.
  • Progress in basic science has identified key pathways and targets involved in articular cartilage deterioration.
  • Dysregulated enzymes like aggrecanases (ADAMTS-4, ADAMTS-5) and collagenases (MMP-13) are central to OA progression.

Purpose of the Study:

  • To review current and emerging therapeutic strategies for osteoarthritis.
  • To highlight novel targets and biotherapeutic approaches for OA management.
  • To discuss clinical considerations for advancing OA therapies.

Main Methods:

  • Review of scientific literature on osteoarthritis pathophysiology and therapeutic targets.
  • Identification of key enzymes, cytokines, and novel biomolecules involved in OA.
  • Analysis of gene expression profiling data for potential therapeutic targets.
  • Consideration of clinical trial and patient stratification factors.

Main Results:

  • Selective protease inhibitors targeting ADAMTS-4, ADAMTS-5, and MMP-13 show promise.
  • Blockade of pro-catabolic cytokines offers a potential therapeutic avenue.
  • Novel biotherapeutics, such as recombinant lubricin, are emerging for intraarticular supplementation.
  • Gene expression profiling reveals upstream targets for intracellular regulators.

Conclusions:

  • Targeting specific proteases and cytokines represents a viable strategy for OA treatment.
  • Emerging biotherapeutics and upstream regulators offer new hope for OA management.
  • Clinical translation requires optimized delivery, validated biomarkers, and patient stratification.

Related Concept Videos

Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...